

This is your new

Health Care Mergers and Acquisitions Answer Book

2018 Edition

Edited by

Andrew L. Bab & Kevin A. Rinker

Debevoise & Plimpton LLP

In clear question-and-answer format, this book brings readers the critical information they need to address the challenges of doing deals in the health care industry, both in the United States and in key markets abroad.

More than fifty experts in the field, led by Andrew L. Bab and Kevin A. Rinker, share their knowledge and substantial practical experience—offering valuable insights and analysis for M&A practitioners and health law specialists, corporate lawyers and outside counsel, private equity deal professionals and industry executives, accountants and investment bankers, and anyone else who needs a detailed overview of health care M&A.

Updated and expanded, this edition includes a new chapter on Health Care M&A Transactions in Japan (chapter 47) that highlights similarities and differences among stock transfers, business transfers, company splits, and other structures used in M&A transactions in Japan. The chapter points out the typical reasons for using each form, its advantages and disadvantages (including from the standpoint of taxation), and basic corporate procedures required for each structure. It outlines the regulatory context for drugs, medical devices, and regenerative medicine products, and touches on other subjects ranging from drug advertising to patent protection for drugs.

This new edition addresses a variety of matters that can prove critical to due diligence for a deal in the health care industry: What kinds of software are regulated by the FDA as medical devices, and what kinds are exempt? How may a patent owner take advantage of the five-year Qualified Infectious Disease Product (QIDP) exclusivity? How will the Drug Enforcement Administration's approach to the opioid epidemic affect manufacturers? How do the EU's General Data Protection Regulation and specific French data privacy laws affect personal health care data in France?

(continued on reverse)

**Practising Law Institute
1177 Avenue of the Americas
New York, NY 10036
#239430**

Further, the 2018 edition assesses the impact of the Tax Cuts and Jobs Act on pharmaceutical companies, emphasizing effects on repatriation of offshore earnings, deferral of taxation of income earned in offshore subsidiaries, inversion transactions, deductible payments to foreign affiliates, and more.

The book also highlights current trends in health care M&A; considers the impact of the current legal and regulatory environment on the health care marketplace; and offers many practice tips and case studies. It provides extensive notes to guide further research. It includes a glossary and table of abbreviations as well as a topical index.

Summary of Contents

Part I: Structuring Health Care M&A Transactions (chapters 1–14) focuses on the various considerations that can have an impact on the structure of a health care M&A transaction: 1 Basic Transaction Structures in Health Care M&A • 2 Contingent Payments • 3 Purchase Price Adjustments • 4 License-and-Collaboration Agreements • 5 Joint Ventures and Strategic Alliances • 6 Transfer of Regulatory Approvals, Licenses, and Clearances • 7 Regulatory Issues in Acquisitions of Health Insurers • 8 Not-for-Profit Issues • 9 Antitrust Considerations • 10 Valuation Issues • 11 Financing Drug Development • 12 Financing of Health Care M&A Transactions • 13 Tax Considerations • 14 Accounting Considerations.

Part II: Due Diligence (chapters 15–33) explores the various industry-specific issues on which a buyer should focus in conducting its due diligence investigation of a health care target: 15 Introduction to Due Diligence in Health Care M&A Transactions • 16 Product Development and Marketing • 17 Patent Extensions and Market Exclusivities • 18 Manufacturing and Distribution Requirements • 19 FDA Investigations and Enforcement • 20 Promotion and Advertising • 21 Compliance with Import and Export Requirements • 22 Miscellaneous Communications with FDA • 23 Compliance with DEA Controlled Substance Requirements • 24 Compliance with Federal and State Health Care Fraud and Abuse Laws • 25 Regulatory Issues in Acquisitions of Health Care Facilities and Physician Practices • 26 Compliance with HIPAA and Other Privacy and Security Laws • 27 Litigation • 28 Intellectual Property • 29 Material Contracts • 30 Environmental Considerations • 31 Employee Benefits • 32 Foreign Corrupt Practices Act • 33 Real Property.

Part III: Transaction Documents (chapters 34–40) discusses the principal elements of a purchase agreement for a health care transaction: 34 Elements of Acquisition Agreements • 35 Representations and Warranties • 36 Covenants and Deal Protection • 37 Closing Conditions • 38 Documentation for Indemnification • 39 Documentation for License-and-Collaboration Agreements • 40 Documentation for Joint Ventures.

Part IV: Special Topics (chapters 41–47) covers several additional topics of interest: 41 Acquisitions of U.S. Companies by Non-U.S. Buyers • 42 Health Care M&A Transactions in France • 43 Health Care M&A Transactions in Germany • 44 Health Care M&A Transactions in Russia • 45 Health Care M&A Transactions in England • 46 Health Care M&A Transactions in Canada • 47 Health Care M&A Transactions in Japan.